After meeting with the FDA, Gilead has decided to suspend its application for the use of Filgotinib in RA in the USA. Safety concerns and the 200 mg dose were factors. Gilead believes it needs approval of 100 & 200 mg dose to be competitive in US market https://t.co/aPFN7hH4zH